The gap will be filled. Not if, but when. Near term 3 stops: 1.50, 1.75, and about 2.30. IMO, 1.75 should be filled by the end of July or earnings, the 2.30 mark will be hit when DVAX announces a new FDA PHIII deal in the works. The FDA announcement should cool some heads, remore uncertainties and pave the road to reaching that goal. Even if DVAX has to raise cash, I'd say it will be in a form of a shelf offering in the low 2's. Partnership a possibility (all though not sure if a good idea) buy-out a real bonus. Either way I am pretty relaxed from here on, as we are on the way to recovery. All IMO of course.